- Home
- NMG vs RXST Comparison
NMG vs RXST Comparison
Compare NMG & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NMG | RXST |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.7M | 305.0M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NMG | RXST |
|---|---|---|
| Price | $2.07 | $7.23 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 10 |
| Target Price | $5.75 | ★ $9.78 |
| AVG Volume (30 Days) | ★ 1.4M | 755.7K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $134,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.60 | $5.90 |
| 52 Week High | $6.06 | $16.73 |
Technical Indicators
Market Signals| Indicator | NMG | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 47.07 | 51.09 |
| Support Level | $2.05 | $6.62 |
| Resistance Level | $2.44 | $7.72 |
| Average True Range (ATR) | 0.15 | 0.39 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 45.52 | 57.83 |
Price Performance
Historical ComparisonAbout NMG Nouveau Monde Graphite Inc.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The company currently operates in two segments: the Matawinie Mine Project and the Battery Material Plant project.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.